US 12,473,570 B2
Zika virus constructs and therapeutic compositions thereof
Vaithilingaraja Arumugaswami, Los Angeles, CA (US); Gustavo Garcia, Jr., Gardena, CA (US); David A. Nathanson, Los Angeles, CA (US); and Ren Sun, Pokfulam (HK)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/609,496
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed May 20, 2020, PCT No. PCT/US2020/033705
§ 371(c)(1), (2) Date Nov. 8, 2021,
PCT Pub. No. WO2020/236874, PCT Pub. Date Nov. 26, 2020.
Claims priority of provisional application 62/850,759, filed on May 21, 2019.
Prior Publication US 2022/0213504 A1, Jul. 7, 2022
Int. Cl. C12N 15/86 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/005 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 14/005 (2013.01); A61K 2039/585 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24132 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24143 (2013.01); C12N 2770/24171 (2013.01)] 12 Claims
 
1. A Zika virus construct comprising a Zika virus genome, wherein said Zika virus genome consists of SEQ ID NO: 7, and wherein said Zika virus construct optionally includes a gene that encodes a mutated E protein comprising SEQ ID NO: 1, wherein the amino acid at position 154 of SEQ ID NO: 1 is any amino acid residue other than asparagine.